Effect of Al substitution on the magnetocaloric properties of La(Fe SiAl)

Here we study the influence of Al doping on the magnetization, heat capacity, and entropy change of La(FeSiAl ) where x = 0, 0.048, and 0.081. When x = 0, the system shows a remarkably sharp heat capacity feature associated with spin fluctuations coincident with, but quite distinct from the latent heat spike of the first order paramagnetic to ferromagnetic phase transition. With the addition of Al the magnetic and calorimetric features become more distributed in field, suggesting that Al adds disorder to the system. For both finite x compositions studied here, the latent heat disappears and the transition can be classified as second order. Although the entropy change associated with the transition is reduced once Al is substituted for Si, the adiabatic temperature change, ΔT is still significant. In La(Fe [Al) the balance between changes in the field dependence of the heat capacity with respect to overall ΔT gain is highlighted, showing that a small amount of Al doping clearly offers some advantage for application

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Effect of Al substitution on the magnetocaloric properties of La(Fe

Here we study the influence of Al doping on the magnetization, heat capacity, and entropy change of La(FeSiAl ) where x = 0, 0.048, and 0.081. When x = 0, the system shows a remarkably sharp heat capacity feature associated with spin fluctuations coincident with, but quite distinct from the latent heat spike of the first order paramagnetic to ferromagnetic phase transition. With the addition of Al the magnetic and calorimetric features become more distributed in field, suggesting that Al adds disorder to the system. For both finite x compositions studied here, the latent heat disappears and the transition can be classified as second order. Although the entropy change associated with the transition is reduced once Al is substituted for Si, the adiabatic temperature change, ΔT is still significant. In La(Fe [Al) the balance between changes in the field dependence of the heat capacity with respect to overall ΔT gain is highlighted, showing that a small amount of Al doping clearly offers some advantage for application

Wie können nanostrukturierte und bio-inspirierte Oberflächen zur Bekämpfung von gefährlichen Keimen beitragen?

Während langen Raumfahrtmissionen sind Astronauten sehr speziellen Umweltbedingungen ausgesetzt. Diese umfassen unter anderem Faktoren wie Schwerelosigkeit, Strahlung, Stress, aber auch Kontaminationen durch Mikroorganismen. Da Mikroorganismen fester Bestandteil des menschlichen Körpers sind z.B. auf der Haut und im Darm, ist die Schaffung einer sterilen Umgebung in der bemannten Raumfahrt unmöglich. Einige dieser Mikroorganismen sind opportunistisch pathogen und können Biofilme bilden, wodurch das Risiko für Infektionen erhöht wird. Dies kann insbesondere ein gesundheitliches Risiko für die Astronauten werden, da die Funktion des Immunsystems unter Weltraumbedingungen reduziert ist. Eine Methode zur Eindämmung der Ausbreitung solcher pathogenen Mikroorganismen in einer Raumstation könnte der Einsatz von antimikrobiellen Oberflächen sein. In dem geplanten ESA Weltraumexperiment BIOFILMS, geht es um die Evaluierung solcher antimikrobiellen Oberflächen. Die zu testenden Oberflächen beinhalten Kupfer, welches bekannterweise antimikrobielle Eigenschaften hat. Mittels des „Direct Laser Interference Patterning“-Verfahren können Nanostrukturen auf den kupferhaltigen Oberflächen generiert werden. Solche Nanostrukturen kommen auch in der Natur vor und verhindern mikrobielle Anheftung und Wachstum aufgrund ihrer besonderen Oberflächeneigenschaften. In den Vorversuchen zum BIOFILMS-Weltraumexperiment konnte nachgewiesen werden, dass kupferhaltige, nanostrukturierte Oberflächen das Wachstum und die Biofilmbildung von Staphylococcus capitis subsp. capitis hemmen

Utility from anticipation and personal equilibrium

Anticipation, Personal equilibrium, Time inconsistency, Disappointment aversion, B49, D89,